The earnings call reflected a mix of achievements and challenges. Cytek Biosciences experienced revenue and adjusted EBITDA growth, driven by international market success and increased service revenues. However, flat product revenue, challenges in the U.S. market, and potential headwinds from NIH funding reductions and currency exchange rates present concerns.
Company Guidance
During Cytek Biosciences' earnings call for the fourth quarter and full year 2024, the company provided several key metrics and guidance for 2025. Full year revenue in 2024 increased by 4% to $200.5 million, with strong service revenue growth and an 8.5% increase in unit volume for Full Spectrum Profiling (FSP) and imaging instruments. Adjusted EBITDA rose by more than 77% from the previous year, reaching $22.4 million. The company repurchased 4 million shares in 2024 and announced a new $50 million repurchase program for 2025. Cytek's 2025 revenue guidance is set between $204 million and $212 million, reflecting 2% to 6% growth over 2024, despite anticipated headwinds such as changes in NIH funding and potential tariff impacts. The company expects continued strong growth in its service business and robust demand in APAC, contrasting with softer conditions in the U.S. and EMEA.
Revenue Growth
Full year revenue in 2024 grew 4% over 2023, reaching $200.5 million, driven by strong growth in service revenue and double-digit growth in international markets outside of the U.S.
Adjusted EBITDA Surge
Adjusted EBITDA of $22.4 million in 2024, a gain of more than 77% above the $12.6 million of adjusted EBITDA from 2023.
Service Revenue Increase
Service revenue grew 8% in Q4 2024 due to the growth in the total installed base of instruments.
International Market Success
Strong demand environment in APAC and the Rest of the World region, with a 21% growth in Asia Pacific driven by strong growth in China.
Cytek Cloud User Growth
Cytek Cloud user base grew by more than 160% from the start of 2024, reaching over 16,000 users.
---
Cytek Biosciences (CTKB) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CTKB Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Feb 27, 2025
$4.81
$4.49
-6.65%
Nov 05, 2024
$5.44
$7.40
+36.03%
Aug 06, 2024
$5.62
$5.09
-9.43%
May 08, 2024
$6.27
$6.20
-1.12%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Cytek Biosciences (CTKB) report earnings?
Cytek Biosciences (CTKB) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Cytek Biosciences (CTKB) earnings time?
Cytek Biosciences (CTKB) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.